Affordable Access

Access to the full text

An overview of GLP-1 agonists and recent cardiovascular outcomes trials

Authors
  • Sheahan, Kelsey H1
  • Wahlberg, Elizabeth A1
  • Gilbert, Matthew P1
  • 1 University of Vermont Medical Center, Burlington, Vermont, USA , Burlington
Type
Published Article
Journal
Postgraduate Medical Journal
Publisher
BMJ
Publication Date
Dec 04, 2019
Volume
96
Issue
1133
Pages
156–161
Identifiers
DOI: 10.1136/postgradmedj-2019-137186
PMID: 31801807
PMCID: PMC7042958
Source
PubMed Central
Keywords
License
Green

Abstract

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are emerging as an important therapy to consider for patients with type 2 diabetes (T2D) given this class of treatment’s ability to reduce glycated haemoglobin and their associated weight loss and low risk for hypoglycaemia. Additionally, seven cardiovascular outcomes trials (CVOTs) have been performed in the past 4 years using lixisenatide, liraglutide, semaglutide, exenatide, albiglutide, dulaglutide and oral semaglutide. All have found non-inferiority for cardiovascular outcomes, with many finding superiority of these drugs. These findings have transformed our guidelines on pharmacological treatment of T2D. This review article will discuss GLP-1 RA therapy, review the seven CVOTs reported to date and discuss the implications on current guidelines and therapies going forward.

Report this publication

Statistics

Seen <100 times